CAS: 1903783-48-1

TK216

TK216 is a potent inhibitor of E26 transformation-specific (ETS) with anticancer activity.

TK216 is a monoclonal antibody that binds with high affinity and specificity to the leukocyte antigen CD19. TK216 is a humanized antibody that inhibits cell proliferation by inducing apoptosis, thereby inhibiting tumor growth. This drug targets CD19-expressing cells and has been shown to be effective in vitro as well as in vivo, where it has shown an inhibitory effect on xenograft tumor growth. TK216 has been evaluated in preclinical studies for its potential to treat hematologic malignancies such as leukemia and lymphoma.